The oncogenic potential of ALK is predominantly driven by genetic alterations, including fusion rearrangements, most notably the EML4-ALK fusion in non-small cell lung cancer, activating point mutations, and gene amplification [4]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.